ReviewPharmaceuticals (Basel, Switzerland)2025
Photodynamic Action of Hypocrellin A and Hypocrellin B against Cancer-A Review.
Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Natural Photosensitizers in Cancer Therapy: A Chemo-Biodiversity Perspective on Light-Activated Natural Compounds.Chemistry & biodiversity · 2026Review
- Natural Product-Based Upconversion-Downshifting Photosensitizers in Photodynamic Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cancer is a major global health concern, affecting nearly 20 million individuals annually, according to the International Agency for Research on Cancer (IARC). There are some unconventional and conventional treatments for cancer. Typically, they span a wide spectrum of conventional and advanced therapeutic approaches, such as photodynamic therapy (PDT). This has long been valued for its non-invasive, targeted, and minimally toxic approach in the management of cancer. More importantly, PDT results in fewer operative and post-operative major complications, faster recovery times, reduced operating time, and saved costs. There are two types of photosensitizers in PDT, including synthetics (e.g., hematoporphyrin derivative, photofrin II, verteporfin) and natural (e.g., Hypocrellin A (HA) and Hypocrellin B (HB)). Nine electronic databases-WanFang Data, PubMed, ScienceDirect, Scopus, Web of Science, Springer Link, SciFinder, and the China National Knowledge Infrastructure (CNKI)-were systematically searched for this review, covering the literature published within the past 20 to 30 years (time range), without language restrictions. Studies were included if they were identified using the keywords Hypocrellin A, Hypocrellin B, photodynamic therapy, and cancer (inclusion criteria). All eligible papers were collected, critically analyzed, and summarized. Duplicate records were excluded during the screening process (exclusion criteria). HA and HB, derived from the fungus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.